1 / 8

Octanate – Factor VIII with the Safety Factor VWF

Octanate – Factor VIII with the Safety Factor VWF. High Purity Plasma-Derived Factor VIII Double Virus Inactivated Haemophilia A Treatment and Prophylaxis. Octanate at a Glance. Physiological factor VIII Naturally stabilised with VWF Highly purified Non denatured

kenyon-craft
Download Presentation

Octanate – Factor VIII with the Safety Factor VWF

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Octanate – Factor VIII with the Safety Factor VWF High Purity Plasma-Derived Factor VIII Double Virus Inactivated Haemophilia A Treatment and Prophylaxis

  2. Octanate at a Glance • Physiological factor VIII Naturally stabilised with VWF Highly purified Non denatured • Extensive clinical use Safe Effective Well-tolerated • State-of-the-art virus safety High quality starting plasma Double virus inactivation: Solvent / Detergent (S/D) treatment Short duration dry heating, 100 °C, 30 min • Convenient handling Small injection volume Easy documentation

  3. Octanate Manufacturing Process Cryoprecipitate Ultrafiltration, diafiltration Resuspension in ethanol-heparin Sterile filtration, filling Aluminium hydroxide addition Lyophilisation, vial closure Adsorption and precipitation Terminal dry heating, 100 °C, 30 min S/D virus inactivation OCTANATE Ion exchange chromatography

  4. Octanate – Viral Safety: Conclusion • Octanate fulfils all current requirements for virus safety set out by regulatory bodies, such as the Committee for Proprietary Medicinal Products* • Two effective steps against lipid enveloped viruses • One effective step against non enveloped viruses • A combination of methods based on different principles of action • Inactivation procedures with a high safety margin • Rapid virus inactivation • Robustness in the event of process variations • Validation of each step with a wide variety of viruses • An individual step efficacy equivalent to 4 log10 • Other process steps provide additional safety *CPMP/BWP/268/95, 1996. CPMP/BWP/269/95 rev 3., 2001

  5. Octanate – Physiologically Stabilised with VWF • Importance of von Willebrand Factor • Biosynthesis of factor VIII VWF imparts correct factor VIII structure and secretion • Stabilisation of factor VIII Protects against unwanted activation and degradation • Transport of factor VIII Directs factor VIII to the site of injury

  6. Octanate – Pharmacokinetics

  7. Octanate – Clinical Efficacy 95.3 % of All Bleeding Episodes Resolved Within 3 Days No. Bleeds 1096 (Total) 167 (Study 1) 374 (Study 2) 213 (Study 3) 342 (Study 4)

  8. Octanate at a Glance – In Daily Clinical Use • Clinical safety and efficacy No inhibitors No virus transmissions Very well tolerated Very good efficacy Successful use in surgery, and in continuous infusion • Convenient handling Small injection volume Easy documentation Pull-off labels Dissolves rapidly Complete application set • Presentation • Storage and shelf-life 24 months shelf-life at + 4 °C to + 8 °C. Do not freeze. Protect from light

More Related